Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gentle zaps may help kids with cerebral palsy stay on their feet

NCT ID NCT05384990

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a very mild, unnoticeable electrical stimulation to the legs can help children and young adults with cerebral palsy (ages 10–21) maintain balance during everyday movements like standing up, walking, and turning. Participants will perform simple tasks while researchers measure their balance and movement. The goal is to find a new way to reduce falls and improve daily function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 21 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for individuals with CP: 1. Age 10-21 2. Diagnosis of CP 3. GMFCS level I-II 4. Ability to stand up from a chair and start walking. 5. Migration index of proximal hip (MIGR) \< 40% femoral head covering in acetabulum 6. At least 0° passive dorsiflexion range of motion (ROM) 7. Sufficient visuoperceptual, cognitive and communication skills 8. Seizure-free or well-controlled seizures 9. No other neurological or musculoskeletal disorders (e.g. dystonia, severe scoliosis, hip instability 10. Ability to communicate pain or discomfort 11. Ability to assent/consent or obtain parent/guardian consent Exclusion Criteria for individuals with CP: 1. Scoliosis with primary curve \> 40% 2. Spinal fusions extending into pelvis 3. Lower Extremity joint instability or dislocation 4. Severe tactile hypersensitivity 5. Lower extremity botulinum injections in the past 6 months 6. Implanted medical device or metal contraindicative of the application of SR 7. Pregnancy (self-reported) 8. Severe lower extremity spasticity (Modified Ashworth Scale score of 4 or greater) 9. History of pulmonary disease limiting exercise tolerance (Asthma Control Test screen) 10. History of cardiac disease (American Heart Association screen) 11. Severely limited range of joint motion/ irreversible muscle contractures 12. Lower extremity surgery or significant injury within last 1 yr. Inclusionary criteria for typically developing volunteers: 1. Aged 10-21 years old 2. Ability to stand up from a chair and start walking without an assistive device or orthoses 3. Able to communicate discomfort during testing and can follow multi-step directions 4. Has not been diagnosed with any neurological or balance disorders 5. Seizure-free Exclusionary criteria for typically developing volunteers: 1. Diagnosis of CP 2. Significant scoliosis with primary curve \> 40° 3. Lower extremity surgery or fractures in the year prior testing 4. Joint instability or dislocation in the lower extremities 5. Severe tactile hypersensitivity 6. A history of selective dorsal root rhizotomy 7. Botulinum toxin injections in the lower extremities within the past 6 months 8. Marked visual or hearing deficits 9. Any embedded metal that may be contraindicated with application of SR 10. Severe spasticity of the lower extremity muscles (eg. a score of 4 on the Modified Ashworth) 11. Pregnancy (self-reported) 12. Severely limited joint range of motion/ irreversible muscle contractures that would not be candidates for soft-tissue surgery 13. Learning disabilities 14. History of neurological disorders 15. Balance and/or postural impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral palsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Delaware

    Newark, Delaware, 19713, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.